Sign in
4

Changes in Ownership

Fulcrum Therapeutics, Inc. Filed Acc 0000950170-25-009813

Options or other derivatives

  • Chief Legal Officer acquired 225,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Oltmans Curtis Gale Chief Legal Officer 2025-01-24 Grant or award · Stock Option (right to buy) +225,000 225,000 D: show line 1 in the form
Loading xslF345X05/ownership.xml…